A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Drilon, Alexander; Fu, Siqing; R. Patel, Manish; Fakih, Marwan; Wang, Ding; J. Olszanski, Anthony; Morgensztern, Daniel; V. Liu, Stephen; Chul Cho, Byoung; Bazhenova, Lyudmila; P. Rodriguez, Cristina; C. Doebele, Robert; Wozniak, Antoinette; L. Reckamp, Karen; Elisabeth Seery, Tara; Nikolinakos, Petros; Hu, Zheyi; Oliver, Jennifer; Trone, Denise; McArthur, Katherine; Patel, Rupal; S. Multani, Pratik; Ahn, Myung‐Ju

doi:10.1158/2159-8290.cd-18-0839

Public

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Published in Cancer Discovery • Nov 28, 2018

Authors:

Alexander Drilon

Siqing Fu

Manish R. Patel

Abstract

Abstract RET fusions are oncogenic drivers of various tumors, including non–small cell lung cancers (NSCLC). The safety and antitumor activity of the multikinase RET inhibitor RXDX-105 were explored in a phase I/Ib trial. A recommended phase II dose of 275 mg fed daily was identified. The most commo...

Subject

VEGF receptors

Cancer research

Chemistry

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!